The NavDx test demonstrates high performance in detecting recurrent disease, providing an enhanced and widely accessible surveillance tool for HPV+ anal squamous cell carcinoma patients.
Mount Sinai Health System and Drs. Eric Genden and Marshall Posner
This article has been updated to clarify the launch date of NavDx and Naveris’ billing policies for patients without insurance coverage.
A blood test to detect circulating tumor DNA accurately predicted recurrence of HPV-driven oropharyngeal cancer after treatment, according to research presented at Multidisciplinary Head and Neck Cancers Symposium.
A blood test was able to accurately predict disease recurrence using circulating tumor tissue modified viral (TTMV)–human papillomavirus (HPV) DNA among patients treated for HPV-driven oropharyngeal squamous cell carcinoma, according to research presented at the 2022 Multidisciplinary Head and Neck Cancers Symposium.
A large, multi-institutional study demonstrates that a blood test to detect circulating tumor DNA can accurately predict recurrence of human papillomavirus (HPV)-driven oropharyngeal cancer following treatment.
